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There is renewed interest in the diagnosis of chronic obstructive pulmonary disease (COPD) within primary care. 
Primary care physicians have difficulty distinguishing asthma from COPD. We tested the feasibility of using 
spirometry and if appropriate, reversibility testing, to identify patients with COPD on asthma registers in primary 
care. 
We carried out a cross-sectional study in three inner-city group practices in east London. Three hundred and 
twenty-eight patients aged 50 years and over on practice asthma registers were invited to attend for spirometry and, 
if appropriate, a trial of oral corticosteroids. The main outcome measures were: feasibility of carrying out 
spirometry; lung function; severity of COPD; prior. diagnosis of COPD; response to a corticosteroid trial; quality of 
life. 
One hundred and sixty-eight of 328 (51%) patients attended for spirometry. According to British Thoracic 
Society criteria, 58 (34%) patients had normal spirometry at the time of assessment; 40 (24%) had active asthma 
and 57 (34%) had COPD. Thirteen patients (8%) were unable to perform spirometry. Of 57 patients with COPD 30 
(53%) had mild, 15 (26%) had moderate and 12 (21%) had severe disease. Twenty-three of 57 (40%) patients with 
COPD on spirometry had this diagnosis recorded prior to the study. New diagnoses of COPD were more likely in 
those with mild or moderate disease (P<O.O5). Twenty-three of 57 (40%) patients with COPD completed a 
corticosteroid trial: one showed significant reversibility of lung function. 
Spirometry was feasible and helped identify patients with COPD on asthma registers in these inner-city practices. 
Patients aged 50 years and over on asthma registers had a wide spectrum of lung function with considerable 
diagnostic misclassification. Some patients with normal lung function when tested may have had well controlled 
asthma. New diagnoses of COPD were mainly in those with mild or moderate disease. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) places an 
enormous burden on healthcare (1). Deaths from COPD 
outnumber those from asthma by more than tenfold (2,3). 
Patients with COPD commonly present in primary care, 
but a reliance on presenting symptoms and lack of 
diagnostic facilities makes it difficult for primary care 
clinicians to distinguish between COPD and asthma (4), 
particularly for patients with features of both conditions. 
Practice asthma registers may therefore include some 
patients with COPD who may benefit from different 
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management. Publication of guidelines has renewed interest 
in the identification of patients with COPD (5,6). Recent 
emphasis on asthma management may have left many older 
patients with unrecognized COPD receiving sub-optimal 
care. There is increasing interest in the use of spriometry in 
general practice (7,8). 
The aim of our study was to test the feasibility of 
carrying out spirometry and, if appropriate, reversibility 
testing, to identify patients with COPD in patients aged 50 
years and over on practice asthma registers. 
Methods 
Three inner-city east London group practices with an 
interest in asthma took part. The practices had list sizes of 
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5004, 10 512 and 6977 patients respectively, with similar 
distributions of patient ages. Practice asthma registers 
comprised 85, 147 and 292 patients aged 50 years or over 
respectively (8.6%, 82% and 20.1% of the practice 
populations in that age group). 
To detect a 10% misclassification rate of patients on 
registers, with 85% certainty at 5% significance, we needed 
to test 170 patients. To achieve this target, we sent written 
invitations outlining the study to 328 patients aged 50 years 
or over on the practices’ registers. These comprised all 85 
and 147 patients from the registers of the first two practices, 
and a one in three sample (96 patients, using a random 
number method) from the third. We excluded four patients 
over 75 years in the third practice since they were involved 
in another research trial. 
We invited patients to attend up to three sessions with a 
respiratory nurse at their surgery. The nurse instructed 
patients to omit inhalers for 12 h before visits. The nurse 
entered details of assessments in patient records. The local 
ethics committee approved the study was part of routine 
care. 
We tested lung function using two identical hand held 
storage spirometers Vitalograph 2120 (Buckingham, U.K.), 
according to European Respiratory Society (ERS) guide- 
lines (9) (best of three readings within 5%), calibrated using 
identical methodology (three discharges of a Vitalograph 11 
calibration syringe before each session). Little or no 
recalibration of instruments was needed between sessions. 
Patients stood during tests and nose-clips were not used. 
The instrument incorporates normal values for patients 
over 70 years of age (10). Volume/time curves were printed 
for each patient immediately after each had completed 
spirometry. Where there was uncertainty, these traces were 
used to review technical success of spirometry and 
diagnostic categories. 
THE FIRST PRACTICE VISIT: 
BRONCHODILATOR REVERSIBILITY 
TESTING 
The nurse took a respiratory history and asked patients to 
complete the St. George’s Respiratory Questionnaire 
(SGRQ) (11). The SGRQ is a validated measure of health 
status for patients with asthma and COPD, consisting of 50 
items with 76 weighted responses and three component 
scores-symptoms, activity and impact. A total score of 
100 represents maximal disability. 
After baseline spirometry, patients received 2.5 mg of 
nebulized salbutamol; followed 20 min later by spirometry 
to assess reversibility.’ Patients with good lung function 
[forced expiratory volume in 1 set (FEVr) < 75% predicted] 
and those with reversibility of impaired lung function (at 
least 15% and 200 ml), termed ‘active asthma’, took no 
further part. Those already taking oral steroids and those 
unable to perform spirometry were also excluded. 
Patients with FEVr ~75% predicted and reversibility of 
less than 15% and 200 ml were defined as,having CQPD 
[based on British Thoracic Society (BTS) draft guidelines at 
time of study design; the BTS subsequently increased this 
criterion to FEVt <80%]. These patients were invited to 
continue in the study. Whilst the BTS guidelines recom- 
mend the additional criterion of a FEVt forced vital 
capacity (FVC) ratio of less than 70%, pilotingwith review 
of spirometry traces by a respiratory specialist (JW) showed 
this limit to exclude patients with COPD who had cut short 
their FVC, giving a spuriously raised ratio. We therefore 
did not apply this criterion. We classified the severity of 
COPD according to FEVr: mild (FEVr 60-75%‘predicted), 
moderate (40-59% predicted) or severe (<40% predicted). 
We searched records of patients found to have COPD on 
spirometry for a diagnosis of COPD recorded as an. active 
problem prior to the study. 
The nurse asked patients with COPD on spirometry to 
stop inhaled corticosteroid treatment and return in 1 
month, and gave written instructions in the event of an 
exacerbation. Patients experiencing an exacerbation (de- 
fined as development of new respiratory symptoms or 
worsening of stable symptoms) during this period restarted 
inhaled corticosteroids and were discontinued from the 
study. 
THE SECOND AND THIRD PRACTICE 
VISITS: CORTICOSTEROID TRIAL 
At the second visit, patients underwent spirometry, and 
were offered 50 mg of oral.prednisolone daily for 14 days or 
500 pg of inhaled beclomethasone dipropionate twice daily 
via large volume spacer for 6 weeks. Compliance was 
assessed by questioning patients directly. At the third visit, 
steriod response; was assessed by spirometry, a positive 
response being an improvement in FEVr of at least 15% 
and 200 mls. 
Lung function and quality of life data were entered onto 
Microsoft Access (Redmond, U.S.A.) and AppleMac 
(California, U.S.A.) databases respectively. SPSS (Waking, 
U.K.) was used for statistical analyses. The Sidak test was 
used to allow for multiple comparisons of quality of life 
scores between patients. 
Results 
ATTENDERS AND NON-ATTENDERS 
One hundred and sixty-eight of 328 (51%) invited patients 
attended for assessment. Non-attenders were not signifi- 
cantly more likely to be male and current smokers than 
attenders (38% vs. 32% male and 40% vs. 30% current 
smokers respectively). Non-attenders were, on average, 
younger than attenders (means 63 vs. 67 years, t= 4.63, 
P<O.OOl). The most common reasons for non-attendance 
were difficulty contacting patients [59 (18% of all invited)] 
or refusal to take part [58 (IS’/,)]. For the majority of those 
whom we could not contact (39/59), we either had an 
IDENTIFICATION OF PATIENTS WITH COPD ON ASTHMA REGISTERS 905 
incorrect telephone number or patients did not have a 
telephone. 
THE FIRST PRACTICE VISIT: 
BRONCHODILATOR REVERSIBILITY 
TESTING 
Of the 168 patients assessed, by British Thoracic Society 
criteria, 58 (34%) had normal lung function; 40 (24%) had 
obstruction reversible by bronchodilator (active asthma) 
and 57 (34%) had obstruction irreversible by bronchodi- 
lator (COPD) (Table 1). Thirteen patients (8%) could not 
perform spirometry, either because of language difficulties 
or problems co-ordinating a forced expiration. 
SEVERITY AND FRIOR DIAGNOSIS OF 
COPD 
Of the 57 patients with COPD, 30 (53%) had* mild, 15 
(26%) had moderate and 12 (21%) had severe disease by 
BTS criteria. Twenty-three patients (40%) had a diagnosis 
of COPD prior to the study. Patients with a prior diagnosis 
were more likely to have severe (eight of 12 patients) rather 
than moderate (eight of 15) or mild (seven of 30) disease 
(x2=3.9, P<O.O5). 
QUALITY OF LIFE SCORES 
There were significant differences in quality of life scores 
between patients with normal lung function and COPD 
(Fig. 1). This held for total and component scores (total, 
mean difference= 11.5, P<O.Ol; impact= 10.0, PcO.05; 
symp-tams= 12.1, PcO.01; and activity= 13.6, P<O.Ol). 
Differences in scores for patients with asthma compared to 
those with normal lung function and with COPD were not 
significant. 
For patients with COPD, quality of life scores were 
worse for those with severe disease compared with 
those with mild and moderate COPD (total, mean 
difference = 15.8, P<O.O5; impact = 19.0, P=O.Ol, 
symptoms= 13.9, P=n.s.; activity= 11.1, P=n.s.) 
THE SECOND AND THIRD PRACTICE 
VISITS: CORTICOSTEROID TRIAL 
Twenty-three of the 57 (40%) patients with COPD 
completed a corticosteroid trial (19 took oral prednisolone; 
four took inhaled corticosteroid), of which only one showed 
a significant spirometric response. Of the 34 patients who 
did not complete a trial, nine suffered exacerbations, six 
failed to adhere to the regimen, four began but stopped due 
to intercurrent illness, two were already taking oral 
corticosteroids, three could no longer be contacted and 10 
patients declined to start a trial. 
Discussion 
This pragmatic study shows that spirometry by a specialist 
nurse was feasible in these British inner-city general 
practices. This technology is not yet part of routine practice 
in spite of its central position in recommendations of U.K. 
TABLE 1. Demography and lung function in patients attending for bronchodilator reversibility testing (Means and SD unless 
otherwise stated) 
Normal spirometry Asthma COPD Poor tests All patients 
No (%) with diagnosis 58 (34) 40 (24) 57 (34) 13 (8) 168 
No (%) men 14 (24) 19 (48) 18 (32) 3 (23) 54 (32) 
Age 64 (8) 67 (11) 69 (8) 72 (8) 67 (9) 
No (%) ‘never’ smokers 23 (40) 8 (20) 9 (16) 5 (39) 45 (26) 
No (%) ex smokers 22 (38) 15 (37) 28 (49) 7 (54) 72 (45) 
No (%) current smokers 13 (22) 17 (43) 20 (35) 1 (8) 51 (30) 
Pack smoking years 33.69 (34.71) 38.75 (29.84) 47.27 (27.45) 28.13 (26.72) 39.94 (30.67) 
(mean and SD)+ 
Pack smoking years 22 (1-126) 32.5 (l-150) 44 (1-114) 19 (5-88) 37 (l-150) 
(median and range)+ 
FEVl (1) 2.13 (0.59) 1.43 (0.49) 1.23 (044) N/A 1.62 (0.65)* 
% predicted FEV, 90.88 (9.05) 62.88 (21.47) 55.79 (15.90) N/A 70.75 (22.15)’ 
FEVr/FVC 0.76 (0.08) 0.62 (0.13) 0.57 (0.13) N/A 0.65 (0.14)’ 
% reversibility 6.15 (4.38) 26.12 (10.95) 9.21 (6.55) N/A 12.55 (11.03) * 
No with > 15% and 200 ml improvement 0 40 0 0 40 
*excluding patients classified as poor tests; +ex smokers and current smokers only. FEVr: forced expiratory volume in 1 set; 
FVC: forced vital capacity. 






Symptoms Activity Impact Total 
Quality of life dimension 
FIG 1. Quality of life scores (mean and 95% Cl, St. George’s Respiratory Questionnaire) in patients with normal lung 
function, asthma and COPD. *P<O.O5 vs. normal, **P<O.Ol vs. normal. n : normal; 4 : asthma; 0 : COPD. 
national COPD guidelines encompassing primary care 
management. We assessed diagnostic accuracy of older 
patients on asthma registers. Just over half of all patients 
invited took up the offer of spirometry. Assessments 
showed a surprising spectrum of lung function, allowing 
us to differentiate patients into three groups, according to 
British Thoracic Society definitions. New diagnoses of 
COPD were more likely in those with mild or moderate 
disease. Only one patient with COPD showed a significant 
response to a corticosteroid trial. 
FACTORS INFLUENCING OUR RESULTS 
Our sampling frame was the practice asthma register. The 
composition of registers will differ between practices 
depending on several factors, including diagnostic criteria 
for asthma, the mechanism used to add patients to registers, 
the duration of register use and the existence of any 
mechanism to remove patients without active disease. The 
third practice in this study had a higher computer recorded 
asthma prevalence across all age groups, reflecting earlier 
use of computer for clinical work and possibly higher local 
prevalence (12). It is possible that some patients with 
asthma or COPD were not on the asthma registers, 
however, case-finding outside the practice registers was 
not our objective. Although our study took place in a multi- 
cultural inner-city area, language problems prevented 
assessment in only six patients. 
Diagnosis of asthma and COPD is a coniroversial area 
and definitions vary across Europe. We used the diagnostic 
criteria of the British Thoracic Society; use of other criteria 
might give different proportions of patients in our 
diagnostic categories. 
PRACTICAL IMPLICATIONS FOR PRIMARY 
CARE 
Patients with normal spirometry 
The patients we categorized as having normal spirometry 
are almost certainly a heterogenous group, probably 
comprised mostly of patients with well controlled asthma, 
some with inactive asthma, some with minor obstructive 
changes and some without lung disease. For example, one 
patient in this group was later found to have breathlessness 
secondary to heart failure. Further study of these patients 
could differentiate between these subgroups. 
Patients with asthma 
We confirmed a diagnosis of asthma in roughly one third of 
patients. This may be a slight under-estimate since, as noted 
above, some patients with normal spirometry may have had 
well controlled asthma. Spriometry may provide a useful 
baseline from which to monitor treatment changes or 
deterioration in lung function over time. Some may 
progress to fulfill criteria for COPD as their lung function 
deteriorates with time. This effect may account for some 
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apparent disease misclassification since patients may have 
been placed on registers many years previously. 
Patients with COPD 
One third of patients had irreversible obstruction. Our 
decision not to apply the BTS criterion of an FEVi/FVC 
ratio of < 70% resulted in the inclusion of only two patients 
with restrictive defects in the COPD group. Only one of 23 
(4%) COPD patients showed a significant response to a 
corticosteriod trial. This is within the range (&38%, mean 
10%) found in a meta-analysis of 15 studies of spirometric 
response to corticosteroids in patients with stable COPD (13). 
Should COPD patients without a corticosteroid 
response stop inhaled steroids? 
The place of inhaled steroids for patients with COPD is 
uncertain (14,15). Bourbeau found no physiological or 
functional benefit of 6 months inhaled corticosteroid in 
patients with severe COPD, suggesting that failure to 
respond to oral corticosterioids selects patients unlikely to 
respond to inhaled corticosteroid (16). Early results ‘of the 
EUROSCOP study (17) suggest that inhaled corticosteroids 
have a small and brief effect on deterioration of lung 
function of patients with mild COPD; results from the 
ISOLDE study (18) (addressing severe COPD) are awaited. 
Whilst inhaled corticosteroids do no prevent COPD 
exacerbations, they may ameliorate them (19). Whilst 
Barnes recommends a trial of high dose inhaled corticos- 
teroids in COPD patients (20), a more practical approach 
(since most are already on this treatment) is to stop inhaled 
corticosteroids and monitor for any changes in FEVi and 
exacerbation rates. Benefits for patients stopping inhaled 
corticosteroids are simplification of complex inhaler re- 
gimes and avoidance of potential adverse effects. Assuming 
the misclassification rate found in this study can be 
generalized to other general practices, a further benefit 
may be considerable savings in National Health Service 
drug budgets. 
Identifying patients with new diagnoses of COPD 
in primary care 
Most of the patients with new diagnoses of COPD had mild 
or moderate disease. Whilst those with severe disease are 
clearly the most important to identify, earlier diagnosis in 
primary care of mild and moderate COPD will allow 
targeting of smoking cessation advice and the offer of other 
management options. 
Quality of life measurements 
Quality of life measurements provided a useful additional 
assessment of disability in this study: they confirmed that 
even patients with mild and moderate COPD had impaired 
quality of life. Disability relates not only to lung function 
but also to factors such as exacerbation rates (21) and 
coping skills. (22) General practitioners are being encour- 
aged to incorporate quality of life measurement into routine 
care: a brief, practical and responsive tool for patients with 
COPD is needed. 
Is spiromety feasible in primary care? 
We found spirometry feasible in these practices. Approxi- 
mately one in five patients declined spirometry and a similar 
proportion could not be contacted. Those that took part 
found assessments acceptable and most COPD patients 
agreed to a corticosteroid trial. Practice nurses were 
enthusiastic about using spirometry, and general practi- 
tioners welcomed more rational diagnosis and management 
of a difficult group of patients. However, several issues are 
unresolved in the use of spirometry in primary care. Firstly, 
skills and experience in performing and interpreting 
spirometry are needed. Specialist respiratory nurses need 
to support practices in starting a service and provide 
additional practice nurse training. Costs to practices in 
staff-time and equipment may need to be met directly. 
Secondly, many practices, especially those without a 
practice nurse, may find referral to a specialist clinic a 
more realistic option. U.K. Primary Care Groups will need 
to contract for direct access spirometry for such practices, 
and support and training for those wishing to carry out 
their own. Advantages for practices using spirometers will 
be offset by opportunity costs. Economic analyses should 
address this. Thirdly, quality control is important in a 
decentralized service; spirometers must be calibrated for 
reliable measurement and results from spirometers without 
pictorial traces are more likely to be misinterpreted. 
Finally, although our results suggest spirometry is useful 
in clarifying diagnoses, its role in guiding management 
decisions in primary care has been questioned and remains 
to be clarified (23). 
DIAGNOSTIC CATEGORIZATION OF 
PATIENTS 
The BTS guidelines present one of several diagnostic 
criteria for COPD (6,24). Such criteria have limitations, 
particularly the separation of patients with a spectrum of 
disease into distinct but somewhat arbitrary categories. 
Nonetheless, our study demonstrates that spirometry used 
in primary care can highlight considerable misclassification. 
The promotion of a more critical approach to diagnosis of 
lung disease in primary care is long overdue. The use of 
more reproducible and objective measures of lung function 
will help, provided adequate training in use and interpreta- 
tion is available. 
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